On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies with annual revenues of more than $15 billion anticipated for 2015.

The combination of Actavis and Forest creates a new breed of specialty pharmaceutical company, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development and a flexible, scalable business model that permits it to adapt quickly to ever-changing industry dynamics and drive sustainable, long-term organic growth.

World-Class Brands Business

The new Actavis (NYSE:ACT) has a world-class brands business competing across multiple market segments. On a pro forma combined basis for full year 2014, Actavis’ brand pharmaceutical business now includes an approximately $2 billion CNS franchise; Gastroenterology (GI) and Women's Health franchises valued at approximately $1 billion each; a Cardiovascular franchise that generates approximately $500 million; and Urology and Dermatology/Established Brand franchises approaching $500 million a year in sales each; as well as emerging and sustainable portfolios in the Infectious Disease and Respiratory therapeutic categories.

Our key marketed brands include BYSTOLIC® (nebivolol), DALIRESP® (roflumilast), FETZIMA® (levomilnacipran extended-release capsules), LINZESS® (linaclotide), NAMENDA® (memantine HCl), NAMENDA XR® (memantine HCl), SAPHRIS® (asenapine), SAVELLA® (milnacipran HCl), TEFLARO® (ceftaroline fosamil) for injection, TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder), and VIIBRYD® (vilazodone HCl).

$1+ Billion Annual Investment in R&D

Actavis invests more than $1 billion annually in the development of distinctive brand and generic products. This commitment is driven by one of the strongest development-focused R&D organizations in the industry, with an emphasis on strategic, innovative development of important durable products that will drive long-term value, and on being the partner of choice for new and existing development collaborations.

Built on Integrity

Actavis proudly and actively promotes professional behavior and personal integrity in every aspect of our business operations. We want to be known both as a resourceful innovator and as a global competitor. However, in matters of integrity there is no room for flexibility or creativity. In everything we do, we expect absolute compliance with the highest ethical standards.

KEY PHARMACEUTICAL PRODUCTS

BYSTOLIC® (nebivolol)
BYSTOLIC full Prescribing Information

DALIRESP® (roflumilast)
DALIRESP full Prescribing Information

FETZIMA® (levomilnacipran extended-release capsules)
FETZIMA full Prescribing Information, including Boxed Warning

LINZESS® (linaclotide)
LINZESS full Prescribing Information, including Boxed Warning

NAMENDA® (memantine HCl)
NAMENDA full Prescribing Information

NAMENDA XR® (memantine HCl)
NAMENDA XR full Prescribing Information

SAPHRIS® (asenapine)
SAPHRIS full Prescribing Information, including Boxed Warning

SAVELLA® (milnacipran HCl)
SAVELLA full Prescribing Information, including Boxed Warning

TEFLARO® (ceftaroline fosamil) for injection
TEFLARO full Prescribing Information

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)
TUDORZA PRESSAIR full Prescribing Information

VIIBRYD® (vilazodone HCl)
VIIBRYD full Prescribing Information, including Boxed Warning

ACTAVIS AT-A-GLANCE

Chairman of the Board: Paul M. Bisaro

CEO & President: Brenton L. Saunders

Corporate Headquarters: Dublin, Ireland

Year Founded: 1984

Employees (global): ~25,000

STOCK EXCHANGE LISTING

New York Stock Exchange (ACT)

WEBSITE

www.Actavis.com